Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Long-Term Investments (2021 - 2023)

Historic Long-Term Investments for AVITA Medical (RCEL) over the last 3 years, with Q2 2023 value amounting to $2.8 million.

  • AVITA Medical's Long-Term Investments fell 5915.76% to $2.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.8 million, marking a year-over-year decrease of 5915.76%. This contributed to the annual value of $6.9 million for FY2022, which is N/A changed from last year.
  • Per AVITA Medical's latest filing, its Long-Term Investments stood at $2.8 million for Q2 2023, which was down 5915.76% from $4.2 million recorded in Q1 2023.
  • AVITA Medical's 5-year Long-Term Investments high stood at $19.8 million for Q3 2021, and its period low was $2.8 million during Q2 2023.
  • For the 3-year period, AVITA Medical's Long-Term Investments averaged around $9.5 million, with its median value being $6.8 million (2022).
  • Its Long-Term Investments has fluctuated over the past 5 years, first crashed by 7973.84% in 2022, then plummeted by 5915.76% in 2023.
  • Quarter analysis of 3 years shows AVITA Medical's Long-Term Investments stood at $19.7 million in 2021, then plummeted by 64.81% to $6.9 million in 2022, then crashed by 60.26% to $2.8 million in 2023.
  • Its Long-Term Investments was $2.8 million in Q2 2023, compared to $4.2 million in Q1 2023 and $6.9 million in Q4 2022.